Cargando…
Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd and International Society of Antimicrobial Chemotherapy.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779261/ https://www.ncbi.nlm.nih.gov/pubmed/33408027 http://dx.doi.org/10.1016/j.ijantimicag.2020.106237 |
| _version_ | 1783631296572948480 |
|---|---|
| author | Gautret, Philippe Hoang, Van Thuan Lagier, Jean-Christophe Raoult, Didier |
| author_facet | Gautret, Philippe Hoang, Van Thuan Lagier, Jean-Christophe Raoult, Didier |
| author_sort | Gautret, Philippe |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7779261 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd and International Society of Antimicrobial Chemotherapy. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77792612021-01-04 Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. Gautret, Philippe Hoang, Van Thuan Lagier, Jean-Christophe Raoult, Didier Int J Antimicrob Agents Letter to the Editor Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2021-01 2021-01-04 /pmc/articles/PMC7779261/ /pubmed/33408027 http://dx.doi.org/10.1016/j.ijantimicag.2020.106237 Text en © 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Gautret, Philippe Hoang, Van Thuan Lagier, Jean-Christophe Raoult, Didier Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| title | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| title_full | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| title_fullStr | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| title_full_unstemmed | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| title_short | Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. |
| title_sort | response to effect estimation of hydroxychloroquine for covid-19: a secondary analysis of an open label non-randomized clinical trial. |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779261/ https://www.ncbi.nlm.nih.gov/pubmed/33408027 http://dx.doi.org/10.1016/j.ijantimicag.2020.106237 |
| work_keys_str_mv | AT gautretphilippe responsetoeffectestimationofhydroxychloroquineforcovid19asecondaryanalysisofanopenlabelnonrandomizedclinicaltrial AT hoangvanthuan responsetoeffectestimationofhydroxychloroquineforcovid19asecondaryanalysisofanopenlabelnonrandomizedclinicaltrial AT lagierjeanchristophe responsetoeffectestimationofhydroxychloroquineforcovid19asecondaryanalysisofanopenlabelnonrandomizedclinicaltrial AT raoultdidier responsetoeffectestimationofhydroxychloroquineforcovid19asecondaryanalysisofanopenlabelnonrandomizedclinicaltrial |